If you follow a ketogenic diet, or you’ve been thinking about starting one, you may have seen the headlines this week and felt your stomach drop a little. On July 15, 2026, MIT researchers published a peer-reviewed study in Nature showing that a ketogenic diet accelerated small intestine tumor growth in mice, sometimes matching or exceeding the tumor rates seen in animals fed an obesogenic high-fat, high-calorie diet. Not because the mice were obese. Not because they were eating junk. Because of how intestinal cells process fat itself. The coverage spread fast: MIT News, EurekAlert, SciTechDaily, MedicalXpress, and the New York Post all ran the story within days, and the keto community has been wrestling with it ever since.

I want to give you a straight read on what this study actually found, why it matters, and what it reasonably means for someone doing keto today. Not panic, not dismissal. Just an honest look.

The study, led by Omer Yilmaz, director of the MIT Stem Cell Initiative and published through MIT’s Koch Institute, is titled “Ketogenic diet mediates intestinal tumorigenesis through lipids not ketones.” That last phrase, “not ketones,” is the part that caught even longtime keto researchers off guard.

Key takeaways
  • MIT's July 15, 2026 Nature study found keto accelerated small intestine tumors in mice, even without obesity.
  • Tumor growth was driven by how cells burn dietary fat, not by ketone bodies (BHB) themselves.
  • A 2022 Nature study showed keto was protective against colon cancer, making effects opposite by gut location.
  • Lead researcher Yilmaz warned that keto's benefits in one tissue can be detrimental in another.
  • These findings are in mice; human clinical implications are not yet established.

What the Study Actually Found (and What It Didn’t)

Here’s the core finding: ketone bodies, specifically beta-hydroxybutyrate (BHB), the molecule most people think of as the active ingredient in ketosis, were identified as “metabolic bystanders.” They weren’t driving the tumor growth. The driver was the way small intestinal cells metabolize dietary fat for fuel. That distinction matters enormously, because the entire premise of “therapeutic ketosis” has rested heavily on BHB as the beneficial agent.

Yilmaz was direct about the implications, telling MIT News that “what might be beneficial for one tissue may be detrimental for another tissue.” That’s not a fringe caveat. That’s the lead researcher flagging that our tissue-specific assumptions about keto have been too broad.

What the study did not show: it did not demonstrate that humans on a ketogenic diet will develop small intestine cancer. Mouse models are useful for identifying biological mechanisms, but they don’t translate directly to human outcomes. The study also didn’t follow animals long-term through a full cancer progression in humans, which involves years of exposure, immune responses, and genetic factors that mice don’t replicate cleanly.

The Colon vs. Small Intestine Contradiction Is a Real Problem

Recommended Nutricost Premium MCT Oil Powder

Zero net carb MCT oil powder that mixes into coffee or smoothies to support ketosis and ketogenic diets.

Check Price →

This is where it gets genuinely complicated. A 2022 study, also published in Nature, showed that a ketogenic diet was protective against colon cancer, and the mechanism pointed to BHB as the protective agent. Now, in 2026, another Nature study from the same institution shows keto accelerating tumor growth in the small intestine, with BHB playing no meaningful role. Two high-quality studies, the same prestigious journal, neighboring segments of the same gastrointestinal tract, opposite conclusions.

The table below shows how the two findings compare side by side:

Feature2022 Nature Study (Colon)2026 Nature Study (Small Intestine)
Diet studiedKetogenicKetogenic
Cancer effectProtectiveTumor-accelerating
Active mechanismBHB (ketone bodies)Dietary fat metabolism
BHB roleProtective agentMetabolic bystander
Model usedMouseMouse
Published inNatureNature

This isn’t a case of bad research on one side. Both studies are serious work. What they’re telling us together is that the GI tract is not one uniform environment, and treating it like one has been a mistake in keto research and promotion alike.

Why the Keto World Got This Wrong for So Long

Part of the problem is that early keto cancer research focused heavily on brain tumors and certain metabolically simple cancers where glucose restriction made intuitive sense. The theory, often called the “metabolic theory of cancer,” holds that cancer cells rely on glucose and can’t efficiently use ketones, so starving them of carbohydrates should slow their growth. That framework has some real support in specific cancers. It was never meant to apply everywhere.

Small intestinal cells, it turns out, are exceptionally good at oxidizing fat. That’s part of their normal job. When you flood them with dietary fat on a ketogenic diet, you’re not depriving cancer cells of fuel, you may be giving certain pre-cancerous intestinal stem cells exactly what they need to proliferate. The mechanism isn’t fully characterized in humans yet, but the mouse data is specific enough that researchers aren’t brushing it off.

Small intestine cancer is also relatively rare compared to colon cancer, which may be one reason this tissue type got less attention in early diet-cancer research. But “rare” doesn’t mean zero risk, and for people with a genetic predisposition or existing GI concerns, these findings carry real weight.

What This Means Practically, Right Now

You might be wondering: should I stop keto? Here’s what I tell people: this study is not a reason for most healthy adults to panic, and it is not a reason to ignore it either.

If you’re doing keto for weight management or blood sugar control and you have no GI history or family history of small intestinal cancer, this finding is worth knowing, worth discussing with your doctor, and not worth catastrophizing over. The human data isn’t there yet. One mouse study, even a rigorous one in Nature, doesn’t overturn a dietary practice for an entire population.

If you’re using keto specifically as a cancer-adjunct therapy, this changes things more urgently. The assumption that keto is broadly anti-cancer is no longer defensible. Anyone using diet therapeutically alongside cancer treatment needs to have a specific, tissue-aware conversation with their oncologist, not a general “keto is anti-inflammatory” conversation.

And if you have a history of small bowel disease, or you’ve been told you’re at elevated risk for GI cancers, this study is worth bringing to a gastroenterologist before continuing or starting a high-fat dietary approach. That’s not alarmism. That’s just using the available evidence responsibly.

The research covered by MIT News and EurekAlert on July 15, 2026 is some of the most important keto-related science published this year precisely because it complicates a story that had gotten oversimplified. Keto isn’t good or bad for cancer. It depends on which cancer, which tissue, which mechanism, and probably which individual. That’s a harder message to put on a wellness podcast, but it’s where the science is pointing.

This field is moving fast enough that what we know in six months may look meaningfully different. Work with a registered dietitian and your medical team if you’re using keto for anything beyond general weight management, and don’t let anyone, including enthusiastic keto advocates or alarmed headline writers, flatten this into something simpler than it is.

Sources

Photo: Lisa from Pexels via Pexels

This article is for general informational purposes only and does not constitute medical or dietary advice. Always consult a licensed healthcare provider or registered dietitian before making significant changes to your diet, especially if you have a medical condition.